AI can draft the appeal. A physician should check whether it's clinically true.
Independent clinical quality control for AI-generated appeal arguments — before they reach the payer.
AI appeal tools are fast. They are not always clinically accurate.
AI-drafted appeals can hallucinate clinical claims that don't exist in the record, miss comorbidities that are critical to the criteria pathway, overstate the strength of the clinical case, and use generic language that a payer reviewer immediately recognizes as non-case-specific. These errors surface only under payer scrutiny — by which time the appeal has already been submitted.
Clinovian provides a physician-level clinical QA layer that sits between the AI draft and the submission. Not competing appeal-writing. A quality-control checkpoint.
The governance context. NIST’s generative-AI risk-management profile emphasizes identifying and governing the risks of generated output rather than assuming it is reliable. A human clinical QA step matters most exactly where AI output will influence a coverage dispute — which is what an appeal is.
Hallucinated clinical claims
Facts asserted in the appeal that do not exist in the patient record or clinical documentation.
Weak criteria logic
Arguments that cite criteria without mapping the patient's actual clinical data to the specific thresholds.
Missing comorbidities
Severity criteria often depend on cumulative comorbidity burden. AI drafts frequently address single-organ narratives.
Generic language
Non-case-specific phrasing that a payer reviewer reads as template output rather than individualized argument.
Payer-policy mismatch
Arguments that cite the wrong criteria pathway, outdated policy, or irrelevant guideline for the specific payer and plan type.
Overstatement risk
Clinical claims that are directionally correct but overstated — creating vulnerability if the payer reviewer examines the record closely.
Claim-by-claim verification
Every material clinical statement in the draft checked against the supplied source record — fabricated, unsupported, contradictory, or overconfident language identified line by line.
A correction table, not a rewrite
Each defect logged with its location, the record evidence, and the recommended correction — a traceable table your team or your model pipeline can act on, not an untraceable replacement draft.
Criteria-pathway review
The draft’s policy logic and applicability checked against the criteria sources the client is authorized to use.
Missing-fact & missed-argument list
Record facts the draft never used — including the comorbidity and severity evidence AI drafts most often leave behind.
Overstatement flags
The specific sentences a payer reviewer could turn against the case, with record-supported alternatives.
A clear disposition
Every review ends in one of three explicit verdicts — so the submission decision is never ambiguous.
Three verdicts. No hedging.
Acceptable with minor edits
The draft is clinically sound; the correction table lists the small fixes to make before submission.
Material revision required
The core argument is salvageable, but specific claims, logic, or policy mapping must change first — each item traceable in the correction table.
Do not submit as written
The draft asserts what the record cannot support. The review says so, with the evidence — because an independent check that never rejects a draft is not a check.
Why independence matters. Clinovian did not build your generation system and is paid to find defects, not to defend the output. That independence is only worth buying because the review is reproducible, source-linked, and willing to reject a draft.
Fits into your existing AI pipeline.
AI Appeal Clinical QA is designed as a pre-submission checkpoint — not a parallel workflow. Your AI tool drafts the appeal, Clinovian reviews it for clinical accuracy and criteria fidelity, and the validated version goes to the payer. Per-batch or monthly retainer, depending on volume.
Inputs required: the exact draft as it would be submitted, the source record it was generated from, and the denial rationale and policy sources your team is authorized to use. Without the original record and the exact draft, the review cannot be performed.
Who this is for: AI appeal-letter startups, AI-RCM vendors, denial-automation platforms, and any team using AI to draft medical-necessity appeals at scale. If your tool generates the draft, the clinical QA layer is what makes it safe to submit.
Positioning: Clinovian is not competing with your AI tool. We are the quality-control layer that makes your AI output defensible.
What this is not: generation of the initial appeal, cybersecurity certification of the AI system, or legal or coding review.
From $250
One draft, one record, one QA review with correction table and disposition. 24–48 hours after complete inputs.
Scoped at intake
Batch size, case mix, and service levels are confirmed at the scope stage before commitment — similar, organized drafts review faster than heterogeneous ones, and the scope reflects that honestly.
Monthly capacity
Ongoing QA flow is priced through Recurring Physician Review Capacity — reserved monthly units, suitability triage, and consolidated invoicing.
During an evaluation, measure what matters: defect detection and correction acceptance against your own baseline — then decide whether to scale.
What the review must resolve before a defensible handoff.
Source fidelity
Is every material clinical claim in the record?
Policy fit
Is the draft using the correct plan, service, setting, line, duration, and pathway?
Completeness
Which comorbidities, prior treatment, objective findings, contraindications, or adverse facts were omitted?
Reasoning
Does the evidence actually support the conclusion?
Disposition
Is the output acceptable with minor edits, materially defective, or unsafe to submit as written?
What the client provides.
Scope and turnaround begin after the agreed inputs are complete enough for a responsible review. A larger record is not automatically a better record.
- Exact generated draft
- Complete source record used to generate it
- Denial letter or request
- Policy or criteria sources cited by the draft
- Generated citations, extracted facts, or trace data when available
What the analysis is designed to prevent.
The page does not assume the adverse decision is wrong. It identifies ways a supportable case can become inaccurate, overstated, or misrouted.
- Reviewing grammar while unsupported claims remain
- Assuming a citation supports the sentence
- Omitting adverse facts because they weaken the appeal
- Rewriting without a traceable correction table
- Scaling batches before sampling heterogeneity and capacity
How this service fits among current alternatives.
- Internal clinician or physician-advisor QA.
- Vendor-integrated human review within an appeal platform.
- Standalone AI appeal generation with staff review.
- General appeal-writing/RCM vendor.
- No independent review, relying on software validation.
Examples include Waystar Appeal Management and Muni Health. Their scope and target customers differ from Clinovian’s proposed independent review.
What can—and cannot—be compared.
Muni publicly advertises the first three AI-drafted appeals free and then $20 per appeal. That is useful evidence for software-generation pricing, but it is not a market rate for independent clinician QA. Enterprise platforms and human-in-the-loop services are generally quote-based. (Muni Health)
When the service is the right instrument.
Choose it when the buyer already has an AI or writer workflow and needs a source-grounded clinical control before submission. Do not choose it as a substitute for legal/coding review, model security validation, or when the original record and exact draft are unavailable. Measure defect detection and correction acceptance during a pilot before scaling.
Send a sample AI-drafted appeal for a QA demonstration.
See what physician-level clinical review catches before the payer does.